Healthcare / BiotechnologyNasdaqGS
$1.31
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-101.2M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-55.4%
↓Gross Margin
N/A
•Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.6%
FCF CAGR
—
FCF margin
-354.9%
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $25.2M · net income $-87.9M · FCF $-89.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $25.2M | $25.2M | $52.3M | $44.8M | $17.2M |
| Net Income | $-87.9M | $-87.9M | $-78.1M | $-68.3M | $-43.6M |
| EBITDA | $-90.7M | $-90.7M | $-83.5M | $-74.3M | $-39.2M |
| EPS | — | — | -2.36 | -1.82 | -1.45 |
| Operating Margin | -380.9% | -380.9% | -170.0% | -175.4% | -259.5% |
| Net Margin | -348.5% | -348.5% | -149.3% | -152.5% | -253.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.19 | -0.36 | -0.25 |
| Current Ratio | 6.42 | 6.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-89.5M | $-89.5M | $-112.2M | $-101.2M | $15.7M |
| Returns | |||||
| ROE | -55.4% | -55.4% | -33.2% | 50.3% | 58.6% |
| Valuation | |||||
| P/B | 0.31 | 0.31 | 0.51 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -51.8% | -51.8% | 16.8% | 160.2% | — |
| EPS Growth | — | — | -29.8% | -25.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.36 → n/d
Residual
-25.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.